Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Mar 15;82(6):1110–1127. doi: 10.1158/0008-5472.CAN-21-1397

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

©2022 The Authors; Published by the American Association for Cancer Research

This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license.

PMC Copyright notice

Figure 6. Combination of RET and ERK inhibitors is synergistic in RET-rearranged cells. A and B, HMSC, HMSC-RET, and SR-Sarc-0001 cells were treated with the indicated combinations of selpercatinib and ulixertinib (A) or selpercatinib and SCH772984 (B) for 96 hours and then cell viability was determined. Loewe synergy analysis was applied to determine each combination synergy score and their statistical significance. Resulting scores are shown as a contour map (top) or a matrix table (bottom). — Combination of RET and ERK inhibitors is synergistic in RET-rearranged cells. A and B, HMSC, HMSC-RET, and SR-Sarc-0001 cells were treated with the indicated combinations of selpercatinib and ulixertinib (A) or selpercatinib and SCH772984 (B) for 96 hours and then cell viability was determined. Loewe synergy analysis was applied to determine each combination synergy score and their statistical significance. Resulting scores are shown as a contour map (top) or a matrix table (bottom).